Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).
Sclerotherapy plus compression showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy alone (moderate certainty).
Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
It is very uncertain whether pazopanib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with placebo (moderate certainty).
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with standard care or placebo (moderate certainty).
Methadone showed no clear difference in serious adverse events for the child compared with buprenorphine (low certainty).
It is very uncertain whether probiotics changes adverse events leading to withdrawal compared with placebo (very low certainty).
It is very uncertain whether combined oral contraceptive pill changes adverse effects ‐ Any adverse events compared with levonorgestrel‐releasing intrauterine system (very low certainty).
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
The intervention led to higher all adverse events and complications; GRADE not reported.
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).